ClinicalTrials.gg
RecruitingNCT04245397Updated Dec 23, 2025

Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome

A Phase 1 interventional study of SX-682 and Decitabine in Myelodysplastic Syndromes, sponsored by Syntrix Biosystems, Inc.. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Syntrix Biosystems, Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2020; still recruiting 6 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
151
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,363 studies in Myelodysplastic Syndromes with a site in United States — 171 open to participants now, 278 under way, 17 of them phase 3. Myelodysplastic Syndromes · United States.

Planned enrollment
139th of 1,189
151 · median 35
Started
2020
with 57 others
Phase 1
384 of 1,363
53 open now
Primary completion
2028-03
later than 181 of 274 live
Registered
1,100th of 1,363
by date

Among the 1,363 studies in Myelodysplastic Syndromes with a site in United States, this one is the 139th largest by planned enrollment of the 1,189 interventional ones that give a count, is one of 58 that started in 2020, is one of 384 in phase 1, reaches primary completion later than 181 of the 274 other live ones, and was the 1,100th registered.

Myelodysplastic Syndromes

1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 318 are open to participants now.

Browse Myelodysplastic Syndromes studies →

Open to participants now

171 of the 1,363 studies in Myelodysplastic Syndromes with a site in United States are open now. Recruiting first, the newest first:

166 more — sign in →

All 171 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 259 Myelodysplastic Syndromes studies recruiting now, 166 (64%) set no upper age limit and 67 (26%) stop at 75 or younger; 55 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,363 studies in Myelodysplastic Syndromes with a site in United States, or all of them as a file.
02

Study summary

This study will determine the safety profile, maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and recommended Phase 2 dose (RP2D) of SX-682 in the treatment of patients with Myelodysplastic Syndromes (MDS).

Read the detailed description

Participants will receive twice daily oral SX-682 for six 28 day cycles. If patients are responding well to the treatment they can continue SX-682 treatment. The first participants will be administered 25 mg orally twice daily. Unless dose limiting toxicities occur, participants will enroll and receive the following increasing twice daily doses of SX-682: 50 mg, 100 mg, 200 mg, and 400 mg.

After establishing the maximum tolerated dose 140 additional participants will be enrolled at the recommended phase 2 dose. Participants will receive continuous SX-682 twice daily oral therapy in 28-day cycles for a total of 6 cycles. The expansion dose cohort will be stratified into IPSS (a) low and intermediate-1 (N=20 SX-682 alone in HMA naive, N=20 SX-682 alone in HMA failure, N=20 SX-682 + DEC-C in HMA-naïve, N=20 SX-682 + DEC-C in HMA-failure) and (b) intermediate-2 and high risk (N=20 SX-682 alone in HMA failure, N=20 SX-682 + DEC-C in HMA-naive, N=20 SX-682 + DEC-C in HMA-failure) MDS. For patients responding well at the end of 6 cycles treatment may continue until disease progression or an adverse event leads to SX-682 discontinuation. Except for blood product transfusions, concurrent therapy for Myelodysplastic Syndromes is not permitted.

03

Conditions studied

  • Myelodysplastic Syndromes

Keywords

  • Immunotherapy
  • Chemokine receptor blockade
  • Myeloid-derived supressor cells
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of MDS by World Health Organization criteria, and either

    1. International Prognostic Scoring System (IPSS) low risk or intermediate-1 risk patients without 5q deletion:

      i. Dose escalation portion: failed prior treatment with at least 4 cycles started of a hypomethylating agent (HMA; azacitidine or decitabine) defined as no response to treatment, loss of response at any time point, or progressive disease/intolerance to therapy.

      ii. Dose expansion portion: failed prior treatment defined as no response to treatment with at least 4 cycles started of HMA, loss of response at any time point, or progressive disease/intolerance to therapy ("HMA failure"); or no prior treatment with HMA ("HMA naive").

    2. IPSS low risk or intermediate-1 risk patients with 5q deletion:

      i. Dose escalation portion: failed prior treatment with at least 4 cycles started of lenalidomide and 4 cycles of hypomethylating agent (azacitidine or decitabine) defined as no response to treatment, loss of response at any time point, or progressive disease/intolerance to therapy.

      ii. Dose expansion portion: same as non-del(5q) lower risk cohort + requirement of failed prior treatment with lenalidomide defined as no response to treatment with at least 4 cycles started of lenalidomide, loss of response at any time point, or progressive disease/intolerance to therapy.

    3. IPSS intermediate-2 risk or high risk patients: HMA failure or HMA naïve as defined above.
  • (ECOG) Performance Status ≤ 2
  • Screening laboratory values:

    1. Renal (GFR) ≥ 30 ml/min;
    2. (AST) / Alanine aminotransferase (ALT) ≤ 3.0 times ;
    3. \< 1.5 times upper limit of normal;
    4. No history of being HIV positive;
    5. No active or infection.
  • ≥ 12 weeks.
  • Women of (WOCBP) must use study specified .
  • WOCBP demonstrate negative pregnancy test.
  • Not breastfeeding.
  • Men sexually active must use study specified contraception.

Exclusion criteria

Exclusion Criteria:

  • Use of chemotherapeutic agents or experimental agents for MDS within 14 days of the first day of study drug treatment.
  • Use of erythroid stimulating agents, Granulocyte-colony stimulating factor (G-CSF), or Granulocyte-macrophage colony-stimulating factor (GM-CSF) within 14 days of the first day of study drug treatment, or during the study.
  • Mean triplicate heart rate- interval (QTc) > 500 msec.
  • Any of the following cardiac abnormalities:

    1. QT interval > 480 msec corrected using Fridericia's formula;
    2. Risk factors for Torsade de Pointes;
    3. Use of medication that prolongs the QT interval with the exception of drugs that are considered absolutely essential for the care of the subject;
    4. Myocardial infarction ≤ 6 months prior to first day of study drug treatment;
    5. Unstable angina pectoris or serious uncontrolled cardiac arrhythmia.
  • Any serious or uncontrolled medical disorder.
  • Prior within the previous 2 years except for local cancers that have been cured; or patients who have been adequately treated and have low risk of reoccurrence.
  • Subjects with a condition requiring systemic treatment with either (> 10 mg daily prednisone equivalents) or other medications within 14 days of study drug administration. Inhaled or topical steroids, and adrenal replacement doses > 10 mg daily prednisone equivalents are permitted in the absence of active disease.
  • Use of other drugs within 30 days of study drug administration.
  • Major surgery within 4 weeks of study drug administration.
  • Live-virus vaccination within 30 days of study drug administration.
  • Allergy to study drug component.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
151 participants (estimated)

Study arms

  • Experimental
    Dose Escalation of SX-682

    Escalating oral doses of SX-682 (study drug) of 25, 50, 100, 200 and 400 mg twice-daily (i.e., 50, 100, 200, 400 and 800 mg total each day.

    Drug: SX-682

  • Experimental
    Expansion of SX-682 alone (lower risk patients, naive to hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in lower risk patients who have never received hypomethylating agents.

    Drug: SX-682

  • Experimental
    Expansion of SX-682 alone (lower risk patients, failed on hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in lower risk patients who failed on hypomethylating agents.

    Drug: SX-682

  • Experimental
    Expansion of SX-682 with decitabine (lower risk patients, naive to hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in lower risk patients who have never received hypomethylating agents.

    Drug: SX-682 · Drug: Decitabine

  • Experimental
    Expansion of SX-682 with decitabine (lower risk patients, failed on hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in lower risk patients who failed on hypomethylating agents.

    Drug: SX-682 · Drug: Decitabine

  • Experimental
    Expansion of SX-682 alone (higher risk patients, failed on hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 200 mg twice daily (recommended phase 2 dose) in higher risk patients who failed on hypomethylating agents.

    Drug: SX-682

  • Experimental
    Expansion of SX-682 with decitabine (higher risk patients, naive to hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in higher risk patients who have never received hypomethylating agents.

    Drug: SX-682 · Drug: Decitabine

  • Experimental
    Expansion of SX-682 with decitabine (higher risk patients, failed on hypomethylating agents)

    Expansion of oral doses of SX-682 (study drug) at 100 mg twice daily with decitabine in higher risk patients who failed on hypomethylating agents.

    Drug: SX-682 · Drug: Decitabine

Interventions

  • DrugSX-682

    SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and CX-C Motif Chemokine Receptor 2 (CXCR2)

  • Decitabine is a hypomethylating agent.

    Also known as: DEC-C

06

What researchers measure

Primary outcomes

  1. SX-682 Maximum Tolerated Dose (MTD)

    Participants cohorts will be enrolled at increasing doses of SX-682. The highest SX-682 dose tested at which no more than 1 of 6 participants experiences a dose limiting toxicity will define the SX-682 MTD

    Time frame: Up to 28 days in the 28 day Cycle 1.

  2. SX-682 Dose Limiting Toxicities (DLT)

    Number of participants experiencing DLTs.

    Time frame: Up to 28 days in the 28 day Cycle 1.

Secondary outcomes

  1. Participants Experiencing a Treatment Response

    The percentage of participants experiencing a complete remission, partial remission, or stable disease according to the International Working Group Response Criteria.

    Time frame: At the end of Cycle 6 (each cycle is 28 days).

  2. SX-682 Delayed Dose Limiting Toxicities

    Number of delayed DLTs experienced by participants.

    Time frame: From the beginning of Cycle 2 to the end of Cycle 6 (each cycle is 28 days).

  3. Adverse Events

    Number of participants experiencing adverse events (AEs).

    Time frame: At the end of Cycle 6 (each cycle is 28 days).

  4. SX-682 Single Dose Maximum Plasma Concentration (Cmax)

    Blood samples will be collected before and after the first dose of SX-682 on Day 1 of Cycle 1.

    Time frame: Day 1 of Cycle 1 (each cycle is 28 days).

  5. SX-682 Steady-State Maximum Plasma Concentration (Css max)

    Blood samples will be collected before and after the first dose of SX-682 on Day 15 of Cycle 1.

    Time frame: Day 15 of Cycle 1 (each cycle is 28 days).

  6. SX-682 Steady-State Minimum Plasma Concentration (Css min)

    Blood samples will be collected before and after the first dose of SX-682 on Day 15 of Cycle 1.

    Time frame: Day 15 of Cycle 1 (each cycle is 28 days).

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2020 (actual). Primary completion is estimated for Mar 2028, 93 months after the start.

Of 84 industry-sponsored phase 1 interventional studies under Myelodysplastic Syndromes, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 72. This study's planned 93 months is above that.

Counting every sponsor, half of 219 studies reached it within 52 months; a quarter within 31 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2020
First posted
Jan 28, 2020
StartActual
Jun 30, 2020
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2029
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04245397
Lead sponsor
Syntrix Biosystems, Inc.
Responsible party
Sponsor
First posted
Jan 28, 2020
Start date
Jun 30, 2020
Primary completion
Mar 2028 (estimated)
Completion
Mar 2029 (estimated)
Last update
Dec 23, 2025

Study contacts

Aaron D Schuler, PhD
Contact
aschuler@syntrixbio.com
253-833-8009 ext. 21
David A Sallman, MD
principal investigator · Moffitt Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SX-682

Start the discussion